Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing

Genes and Development

Volumn 28, Issue 11, 2014, Pages 1191-1203

  Xu, Yilin ^a   Gao, Xin D ^a   Lee, Jae Hyung ^b,e   Huang, Huilin ^a   Tan, Haiyan ^c   Ahn, Jaegyoon ^b   Reinke, Lauren M ^a   Peter, Marcus E ^a   Feng, Yue ^d   Gius, David ^a   Siziopikou, Kalliopi P ^a   Peng, Junmin ^c   Xiao, Xinshu ^b   Cheng, Chonghui ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Kyung Hee University   (South Korea)

Author keywords

Alternative splicing; Breast cancer metastasis; CD44; EMT; ESRP1; hnRNPM; TGF

Indexed keywords

HERMES ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN M; TRANSFORMING GROWTH FACTOR BETA;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL TYPE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXON SKIPPING; FEMALE; HUMAN; HUMAN CELL; MESENCHYME CELL; METASTASIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; BREAST CANCER METASTASIS; CD44; EMT; ESRP1; HNRNPM; TGFΒ;

ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP M; HUMANS; MICE; NEOPLASM METASTASIS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84901746783     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.241968.114     Document Type: Article

References (63)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 100: 3983-3988.
2. Anczukow O., Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK, Krainer AR. 2012. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 19: 220-228.
3. Aslakson C.J., Miller FR. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405.
4. Bahn J.H., Lee JH, Li G, Greer C, Peng G, Xiao X. 2012. Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res 22: 142-150.
5. Bidus M.A., Risinger JI, Chandramouli GV, Dainty LA, Litzi TJ, Berchuck A., Barrett JC, Maxwell GL. 2006. Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Clin Cancer Res 12: 83-88.
6. Bonomi S., di Matteo A, Buratti E, Cabianca DS, Baralle FE, Ghigna C., Biamonti G. 2013. HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition. Nucleic Acids Res 41: 8665-8679.
7. Brown R.L., Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J., Cheng C. 2011. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 121: 1064-1074.
8. Buckanovich R.J., Posner JB, Darnell RB. 1993. Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 11: 657-672.
9. Busch A., Hertel KJ. 2012. Evolution of SR protein and hnRNP splicing regulatory factors. Wiley Interdiscip Rev RNA 3: 1-12.
10. Cheng C., Sharp PA. 2006. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol 26: 362-370.
11. Cheng C., Yaffe MB, Sharp PA. 2006. A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 20: 1715-1720.
12. Dalerba P., Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A., Huang EH, Simeone DM, et al. 2007. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci 104: 10158-10163.
13. Das S., Anczukow O, Akerman M, Krainer AR. 2012. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell reports 1: 110-117.
14. Datar K.V., Dreyfuss G, Swanson MS. 1993. The human hnRNP M proteins: identification of a methionine/arginine-rich repeat motif in ribonucleoproteins. Nucleic Acids Res 21: 439-446.
15. De Craene B, Berx G. 2013. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110.
16. Dittmar K.A., Jiang P, Park JW, Amirikian K, Wan J, Shen S, Xing Y, Carstens RP. 2012. Genome-wide determination of a broad ESRP-regulated posttranscriptional network by high-throughput sequencing. Mol Cell Biol 32: 1468-1482.
17. Farmer P., Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, et al. 2005. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24: 4660-4671.
18. Fedorchenko O., Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P., Eckei L, Breuer A, Crispatzu G, Rosen N, Landwehr T, et al. 2013. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood 121: 4126-4136.
19. Han S.P., Tang YH, Smith R. 2010. Functional diversity of the hnRNPs: past, present and perspectives. Biochem J 430: 379-392.
20. Herishanu Y., Gibellini F, Njuguna N, Hazan-Halevy I, Farooqui M, Bern S, Keyvanfar K, Lee E, Wilson W, Wiestner A. 2011. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma 52: 1758-1769.
21. Hiraga T., Ito S, Nakamura H. 2013. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res 73: 4112-4122.
22. Horiguchi K., Sakamoto K, Koinuma D, Semba K, Inoue A, Inoue S, Fujii H, Yamaguchi A, Miyazawa K, Miyazono K, et al. 2012. TGF-β drives epithelial-mesenchymal transition through dEF1-mediated downregulation of ESRP. Oncogene 31: 3190-3201.
23. Hovhannisyan R.H., Carstens RP. 2007. Heterogeneous ribonucleoprotein m is a splicing regulatory protein that can enhance or silence splicing of alternatively spliced exons. J Biol Chem 282: 36265-36274.
24. Huelga S., Vu A, Arnold J, Liang T, Liu P, Yan B, Donohue J, Shiue L, Hoon S, Brenner S et al. 2012. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Reports 1: 167-178.
25. Jin Y., Suzuki H, Maegawa S, Endo H, Sugano S, Hashimoto K, Yasuda K., Inoue K. 2003. A vertebrate RNA-binding protein Fox-1 regulates tissue-specific splicing via the pentanucleotide GCAUG. EMBO J 22: 905-912.
26. Jin L., Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. 2006. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174.
27. Li C., Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. 2007. Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
28. Li G., Bahn JH, Lee JH, Peng G, Chen Z, Nelson SF, Xiao X. 2012. Identification of allele-specific alternative mRNA processing via transcriptome sequencing. Nucleic Acids Res 40: e104.
29. Liu R., Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G., Lewicki J, Shedden K, Clarke MF. 2007. The prognostic role of a gene signature from tumorigenic breastcancer cells. N Engl J Med 356: 217-226.
30. Lovci M.T., Ghanem D, Marr H, Arnold J, Gee S, Parra M, Liang TY, Stark TJ, Gehman LT, Hoon S, et al. 2013. Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges. Nat Struct Mol Biol 20: 1434-1442.
31. Mani S.A., Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M., Reinhard F, Zhang CC, Shipitsin M, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
32. Markovtsov V., Nikolic JM, Goldman JA, Turck CW, Chou MY, Black DL. 2000. Cooperative assembly of an hnRNP complex induced by a tissue-specific homolog of polypyrimidine tract binding protein. Mol Cell Biol 20: 7463-7479.
33. Matter N., Herrlich P, Konig H. 2002. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420: 691-695.
34. Matunis M.J., Xing J, Dreyfuss G. 1994. The hnRNP F protein: unique primary structure, nucleic acid-binding properties, and subcellular localization. Nucleic Acids Res 22: 1059-1067.
35. Mauger D.M., Lin C, Garcia-Blanco MA. 2008. hnRNP H and hnRNP F complex with Fox2 to silence fibroblast growth factor receptor 2 exon IIIc. Mol Cell Biol 28: 5403-5419.
36. McBryan J, Howlin J, Kenny PA, Shioda T, Martin F. 2007. ERα-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene 26: 6406-6419.
37. Mima K., Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, et al. 2012. CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 72: 3414-3423.
38. Minn A.J., Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. 2005. Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
39. Onder T.T., Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. 2008. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3654.
40. Perou C.M., Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000. Molecular portraits of human breast tumours. Nature 406: 747-752.
41. Polydorides A.D., Okano HJ, Yang YY, Stefani G, Darnell RB. 2000. A brain-enriched polypyrimidine tract-binding protein antagonizes the ability of Nova to regulate neuron-specific alternative splicing. Proc Natl Acad Sci 97: 6350-6355.
42. Prat A., Perou CM. 2011. Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23.
43. Prince M.E., Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P., Weissman IL, Clarke MF, Ailles LE. 2007. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci 104: 973-978.
44. Rakha E.A., El-Sayed ME, Reis-Filho J, Ellis IO. 2009. Pathobiological aspects of basal-like breast cancer. Breast Cancer Res Treat 113: 411-422.
45. Reinke L.M., Xu Y, Cheng C. 2012. Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition. J Biol Chem 287: 36435-36442.
46. Rickman D.S., Millon R, De Reynies A, Thomas E, Wasylyk C, Muller D., Abecassis J, Wasylyk B. 2008. Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene 27: 6607-6622.
47. Sarrio D., Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G., Palacios J. 2008. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989-997.
48. Shapiro I.M., Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay M.H., Burge CB, Gertler FB. 2011. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 7: e1002218.
49. Shen S., Park JW, Huang J, Dittmar KA, Lu ZX, Zhou Q, Carstens RP, Xing Y. 2012. MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data. Nucleic Acids Res 40: e61.
50. Sorlie T., Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T., Eisen MB, van de Rijn M, Jeffrey SS, et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98: 10869-10874.
51. Sotiriou C., Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. 2006. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
52. Swanson M.S., Dreyfuss G. 1988. RNA binding specificity of hnRNP proteins: a subset bind to the 39 end of introns. EMBO J 7: 3519-3529.
53. Thiery J.P., Sleeman JP. 2006. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
54. Thomas P., Forse RA, Bajenova O. 2011. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin Exp Metastasis 28: 923-932.
55. Thomson S., Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD. 2011. A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 28: 137-155.
56. Underwood J.G., Boutz PL, Dougherty JD, Stoilov P, Black DL. 2005. Homologues of the Caenorhabditis elegans Fox-1 protein are neuronal splicing regulators in mammals. Mol Cell Biol 25: 10005-10016.
57. Valacca C., Bonomi S, Buratti E, Pedrotti S, Baralle FE, Sette C, Ghigna C., Biamonti G. 2010. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol 191: 87-99.
58. vant Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse H.L., van der Kooy K, Marton MJ, Witteveen AT, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
59. Venables J.P., Brosseau JP, Gadea G, Klinck R, Prinos P, Beaulieu JF, Lapointe E, Durand M, Thibault P, Tremblay K, et al. 2013. RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Mol Cell Biol 33: 396-405.
60. Warzecha C.C., Sato TK, Nabet B, Hogenesch JB, Carstens RP. 2009. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 33: 591-601.
61. Warzecha C.C., Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S, Guo W., Xing Y, Carstens RP. 2010. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 29: 3286-3300.
62. Xu P., Duong DM, Peng J. 2009. Systematical optimization of reverse-phase chromatography for shotgun proteomics. J Proteome Res 8: 3944-3950.
63. Yang J., Weinberg RA. 2008. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829.